News – Page 1040 – Endpoints News

Pfizer’s PhIII kidney cancer study for Inlyta flops as investigators flag a dead end on outcomes

8 years ago

Biotech resurrects a long faded Novartis cancer drug star, using a biomarker strategy to push ahead

8 years ago

Pfizer heads to the Hudson, signs 20-year lease at posh new NYC headquarters

8 years ago

Tapping a biotech boom, China gene editing CRO Biocytogen bags $65M round for global expansion

8 years ago

Frazier adds $780M fund for its ‘growth buyout’ team; FDA pushes back its deadline on AbbVie's elagolix; ...

8 years ago

Buckle up: Biotech board activist Alex Denner is out to shake things up at Ironwood

8 years ago

After yet another PhIII Alzheimer's failure, experts try to map a path out of the wrecking field

8 years ago

The drumbeat of Alzheimer’s PhIII failures continues as vTv drug is outperformed by a placebo, shares crash

8 years ago

Top AstraZeneca I/O vet Robert Iannone jumps to Immunomedics as R&D chief as BLA looms

8 years ago

Magenta bags $52M Series C for bone marrow transplant pipeline

8 years ago

AbbVie’s promised rheumatoid arthritis blockbuster upadacitinib hits its marks in another PhIII — this time ...

8 years ago

Therapix shares rise on early data of its repurposed cannabinoid in Tourette syndrome

8 years ago

AstraZeneca licenses Ionis' NASH drug for $30M as momentum builds in the field

8 years ago

Acadia shares plunge after CNN probes Nuplazid deaths; Agios shares surge on report that a shaky Celgene is scouting ...

8 years ago

Merck racks up another win in wide-ranging PhIII Keytruda lung cancer study, this time as solo therapy

8 years ago

Constellation joins the mega-round club with $100M raise and plans to pursue cancer studies

8 years ago

Novartis CEO Vas Narasimhan cuts loose an old anchor and sets sail with $8.7B AveXis buyout

8 years ago

Menlo’s IPO hangover begins with a failed PhII for an old Merck castoff

8 years ago

Abeona appoints new chief as Timothy Miller moves to CSO; Maxine Gowen passes Trevena baton to Carrie Bourdow; Scott ...

8 years ago

With a deadline looming, Takeda CEO Weber woos analysts for support of a Shire buyout

8 years ago

Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal

8 years ago

Celltrion receives CRLs for Rituxan, Herceptin biosimilars

8 years ago

Keytruda/epacadostat combo crashes in PhIII melanoma study, raising questions about the future of IDO for Incyte

8 years ago

Leap of faith? Buzzy anti-aging biotech Unity pitches an $85M IPO based on mouse data

8 years ago

First page Previous page 1037 1038 103910401041 1042 1043 Next page Last page